Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Maraviroc + darunavir/ritonavir versus emtricitabine/tenofovir + darunavir/ritonavir in treatment-naive CCR5-tropic HIV-1
2010-021785-30Phase 3Completed
- Sponsor
- ViiV Healthcare
- Start
- Sep 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in human immunodeficiency virus infection (HIV) and Human immunodeficiency virus infection type 1 comparing Maraviroc + darunavir/ritonavir with Emtricitabine/tenofovir + darunavir/ritonavir (2 arms). Primary endpoint: Proportion of subjects with plasma HIV-1 RNA <50 copies/mL at Week 48. Started Sep 2011; status: completed.
02
Drugs
maravirocemtricitabinetenofovir disoproxil fumaratedarunavirritonavir
03
Conditions
human immunodeficiency virus infection (HIV)Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on 2010-021785-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-021785-30.